-
Selective Hypothermic Albumin Perfusion in Stroke
2026-08-12
A 2026 Translational Stroke Research study reports that intra-arterial selective cooling human serum albumin infusion provided stronger neuroprotection than selective cooling saline or albumin-only strategies in a rat middle cerebral artery occlusion model. The findings connect targeted hypothermia and local albumin delivery with reduced neuroinflammation, improved blood-brain barrier integrity, and inhibition of the ROCK1/MLC–F-actin pathway.
-
C34: A TLR4 Inhibitor for Assay Design
2026-08-12
C34 is a selective TLR4 inhibitor for resolving pathway-specific inflammatory responses. This article positions C34 as a mechanistic calibration control, using recent Taxus chinensis neuroinflammation findings to guide assay interpretation across macrophage, enterocyte, and microglial models.
-
Hydrocortisone in Translational Assay Design
2026-08-11
Learn how Hydrocortisone supports controlled glucocorticoid receptor, barrier, neuroprotection, and prostate-mechanism experiments. This workflow emphasizes stock preparation, orthogonal readouts, reference-study translation, and troubleshooting for reproducible inflammation model research.
-
Rotavirus Infection, Nrf2 Decline, and Redox Defense
2026-08-11
The reference study shows that rotavirus infection produces a biphasic Nrf2 response: an early, oxidative stress-associated increase followed by a pronounced decline in Nrf2 abundance, nuclear availability, and target-gene expression. Its major contribution is linking late Nrf2 depletion to proteasome-dependent, K48-linked ubiquitination rather than simply to persistent cellular oxidation, providing a mechanistic framework for oxidative stress research in viral infection.
-
Angiotensin Peptides and SARS-CoV-2 Spike Binding
2026-08-10
The 2025 reference study identifies naturally occurring angiotensin peptide fragments as modulators of SARS-CoV-2 spike binding to host receptors, with especially strong effects observed for shorter and N-terminally truncated peptides. Its antibody-based binding design provides a mechanistic framework for studying how renin-angiotensin system peptides may connect cardiovascular signaling with viral-entry biology, while remaining distinct from direct infection or clinical evidence.
-
AMPK–SQSTM1 Feedback Under Metabolic Stress
2026-08-09
A 2024 AUTOPHAGY study identifies a double-positive feedback loop linking AMPK and SQSTM1/p62 during metabolic stress. The mechanism couples lysosomal deacidification, TFEB/TFE3 regulation, TAK1-dependent p62 phosphorylation, KEAP1 degradation, and NRF2 activation, clarifying how cancer cells coordinate energy and antioxidant defenses.
-
Fenofibrate: Designing PPARα–YAP Assays
2026-08-08
Fenofibrate is more than a PPARα agonist: it is a useful perturbation tool for separating receptor engagement, liver growth, YAP signaling, and cytotoxicity. This guide translates age-comparative mouse evidence into practical assay design and interpretation decisions.
-
Antimycin A4: From Target Biology to Assay Design
2026-08-07
Antimycin A4 is a dual-pathway ATP-citrate lyase inhibitor and mitochondrial respiratory chain inhibitor. This article explains how to separate lipid-biosynthesis effects from respiratory-chain stress and translates a synthetic chemistry paper into practical assay-design principles.
-
Bafilomycin A1: Precision V-ATPase Inhibitor for Lysosomal R
2026-08-07
Bafilomycin A1 enables targeted, reversible inhibition of V-ATPase activity, empowering advanced studies in intracellular pH regulation and autophagy. Discover how this benchmark compound from APExBIO delivers robust, reproducible data for lysosomal function assays and immune cell modeling.
-
High-Throughput BBB Permeability Modeling with Lysosomal Cor
2026-08-06
Hu et al. present a robust high-throughput in vitro blood-brain barrier (BBB) model using LLC-PK1-MOCK/MDR1 cells, integrating lysosomal trapping correction to improve prediction of CNS drug permeability. This surrogate barrier system accurately correlates in vitro permeability with in vivo brain distribution, offering a cost-efficient platform for early CNS drug screening.
-
Intranasal Sumatriptan as First-Line Pediatric Migraine Ther
2026-08-06
This study evaluates the use of intranasal sumatriptan as an initial treatment for pediatric migraine in the emergency department. Its findings suggest that intranasal sumatriptan not only reduces pain scores but also streamlines care by decreasing the need for IV therapies and shortening length of stay, offering a practical shift in acute pediatric migraine management.
-
MEG3 Modulation of TGF-β1/PI3K/AKT in NiO NP-Induced Lung Fi
2026-08-05
This study reveals that the long noncoding RNA MEG3 attenuates nickel oxide nanoparticle (NiO NP)-induced pulmonary fibrosis by inhibiting the TGF-β1-mediated PI3K/AKT pathway. The findings highlight mechanistic links between nanoparticle exposure, fibrogenic signaling, and RNA-based modulation, providing a foundation for targeted intervention strategies in fibrosis research.
-
Applied Workflows with Mubritinib (TAK 165): Complex I Inhib
2026-08-05
Mubritinib (TAK 165) offers precise, selective inhibition of mitochondrial complex I, making it a powerful tool for studying chemoresistant AML and HER2-driven cancer models. This guide delivers actionable protocols, troubleshooting insights, and contextualizes the latest evidence for maximizing experimental success.
-
Phenacetin in hiPSC-Derived Intestinal Organoids: Protocols
2026-08-04
Explore how Phenacetin (N-(4-ethoxyphenyl)acetamide) empowers pharmacokinetic research using advanced hiPSC-derived intestinal organoids. This guide delivers actionable workflows, troubleshooting strategies, and evidence-based parameter choices to maximize the reliability and translational value of your drug absorption studies.
-
Spinosad Targets CHRNA5-EGFR Axis to Suppress Lung Adenocarc
2026-08-04
The referenced study uncovers a novel anti-proliferative mechanism in lung adenocarcinoma, where spinosad disrupts CHRNA5-mediated EGFR signaling. These findings provide mechanistic insight into tumor growth inhibition and suggest new avenues for therapeutic development targeting nicotinic acetylcholine receptor pathways.